Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers

Woo, Han Min; Kim, Kyung Mi; Choi, Man Ho; Jung, Byung Hwa; Lee, Jeongae; Nam, Seok Jin; Kim, Sung Hoon; Bai, Sang Wook; Chung, Bong Chul

doi:10.1016/j.cca.2008.10.014

Cited by 170 publications

(115 citation statements)

References 21 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…The sample preparation procedure and LC-MS/MS condition of m1A were described in a previous study. [43][44][45] LC-MS/MS was comprised of a NANOSPACE SI-2 HPLC system and a TSQ Quantum Ultra (Thermo Fisher Scientific) triple quadrupole mass spectrometer equipped with a heated electrospray ionization source. Samples were analyzed in selected reaction monitoring mode.…”

Section: Measurement Of Circulating Free M1amentioning

confidence: 99%

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Mishima

Inoue

Saigusa³

et al. 2014

Journal of the American Society of Nephrology

104

View full text Add to dashboard Cite

Tissue damage by oxidative stress is a key pathogenic mechanism in various diseases, including AKI and CKD. Thus, early detection of oxidative tissue damage is important. Using a tRNA-specific modified nucleoside 1-methyladenosine (m1A) antibody, we show that oxidative stress induces a direct conformational change in tRNA structure that promotes subsequent tRNA fragmentation and occurs much earlier than DNA damage. In various models of tissue damage (ischemic reperfusion, toxic injury, and irradiation), the levels of circulating tRNA derivatives increased rapidly. In humans, the levels of circulating tRNA derivatives also increased under conditions of acute renal ischemia, even before levels of other known tissue damage markers increased. Notably, the level of circulating free m1A correlated with mortality in the general population (n=1033) over a mean follow-up of 6.7 years. Compared with healthy controls, patients with CKD had higher levels of circulating free m1A, which were reduced by treatment with pitavastatin (2 mg/d; n=29). Therefore, tRNA damage reflects early oxidative stress damage, and detection of tRNA damage may be a useful tool for identifying organ damage and forming a clinical prognosis.

show abstract

Section: Measurement Of Circulating Free M1amentioning

confidence: 99%

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Mishima

Inoue

Saigusa³

et al. 2014

Journal of the American Society of Nephrology

104

View full text Add to dashboard Cite

show abstract

“…Although these profiling approaches focus on upstream genetic and protein variations, metabolomics captures the global metabolic changes that occur in response to pathological, environmental or lifestyle factors (12). Consequently, metabolomics complements the information obtained by genomics and proteomics (13) and has already shown promise in identifying metabolite-based biomarkers in prostate (14), breast (15), ovarian (16), brain (17), and oral (18) cancers. Recently metabolomic study of HCC has been performed by high resolution magic-angle spinning 1 H nuclear magnetic resonance spectroscopy (19) and a panel of 13 differential tissue metabolites, including alanine, leucine and glucose were identified.…”

Section: Hepatocelluar Carcinoma (Hcc)mentioning

confidence: 99%

Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma

Chen

Xie

Wang

et al. 2011

Molecular & Cellular Proteomics

264

118

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignancy in the world with high morbidity and mortality rate. Identification of novel biomarkers in HCC remains impeded primarily because of the heterogeneity of the disease in clinical presentations as well as the pathophysiological variations derived from underlying conditions such as cirrhosis and steatohepatitis. The aim of this study is to search for potential metabolite biomarkers of human HCC using serum and urine metabolomics approach. Sera and urine samples were collected from patients with HCC (n ‫؍‬ 82), benign liver tumor patients (n ‫؍‬ 24), and healthy controls (n ‫؍‬ 71). Metabolite profiling was performed by gas chromatography time-of-flight mass spectrometry and ultra performance liquid chromatography-quadrupole time of flight mass spectrometry in conjunction with univariate and multivariate statistical analyses. Forty three serum metabolites and 31 urinary metabolites were identified in HCC patients involving several key metabolic pathways such as bile acids, free fatty acids, glycolysis, urea cycle, and methionine metabolism. Differentially expressed metabolites in HCC subjects, such as bile acids, histidine, and inosine are of great statistical significance and high fold changes, which warrant further validation as potential biomarkers for HCC. However, alterations of several bile acids seem to be affected by the condition of liver cirrhosis and hepatitis. Quantitative measurement and comparison of seven bile acids among benign liver tumor patients with liver cirrhosis and hepatitis, HCC patients with liver cirrhosis and hepatitis, HCC patients without liver cirrhosis and hepatitis, and healthy controls revealed that the abnormal levels of glycochenodeoxycholic acid, glycocholic acid, taurocholic acid, and chenodeoxycholic acid are associated with liver cirrhosis and hepatitis. HCC patients with alpha fetoprotein values lower than 20 ng/ml was successfully differentiated from healthy controls with an accuracy of 100% using a panel of metabolite markers. Our work shows that metabolomic profiling approach is a promising screening tool for the diagnosis and stratification of HCC patients.Molecular & Cellular Proteomics 10: 10.1074/mcp.M110.004945, 1-13, 2011. Hepatocelluar carcinoma (HCC)1 is the fifth most common cancer (1) and the third leading cause of cancer-related death (2) with a five-year survival rate of less than 7% (3). The morbidity of HCC in Southeast Asia and sub-Saharan Africa is greater than 20 cases per 100,000 population, whereas in North America and Western Europe is much lower, less than 5 per 100,000 population (4). However, a dramatically increasing incidence of HCC in the world, especially in the United States has been reported in recent years, primarily because of chronic alcohol use and chronic hepatitis C infection (5). Diabetic and metabolic diseases of the liver have been known to contribute to an increased incidence of HCC in recent years (6, 7). Despite significant progress in cancer diagnosis and treatment, the morbidity...

show abstract

“…Another metabolomic study performed by Zhang et al also reported 22 differential metabolites of ovarian cancer; moreover, four of them, including N4-acetylcytidine, pseudouridine, urate-3-ribonucleoside and succinic acid, exhibited suitability as predictors for the outcomes of tumor resection [69]. Some differential metabolites of ovarian cancer in serum [70] and urine [71] were recently reported.…”

Section: Gynecologic Cancermentioning

confidence: 92%

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Yin

2013

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Early detection is the most effective way to improve the clinical outcome of malignancies. Although some tumor markers are now widely used in the clinic, their sensitivity and specificity are still not satisfactory. Thus, there is an urgent requirement for the discovery of new tumor markers. By measuring holistic endogenous metabolites, metabolomics can be used for delineating metabolic networks and discovering metabolic markers. Chromatography-mass spectrometry is the most widely used tool for metabolomics and has shown great potential for biomarker screening. In this review, the authors summarize: recent advances in the protocols and methodologies of chromatography-mass spectrometry-based metabolomics in the discovery of tumor markers; recently identified tumor metabolic markers for primary liver cancer, gynecologic cancer and genitourinary cancer and their applications; and commonly encountered problems in the translational research of metabolic markers.

show abstract

Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers

Cited by 170 publications

References 21 publications

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma

Metabolomics for tumor marker discovery and identification based on chromatography–mass spectrometry

Contact Info

Product

Resources

About